Translated by: MOS Education Team – Marco Polo
According to a report from Zero Hedge on October 11, Merck officially applied for emergency authorization for Molnupiravir to treat COVID-19 to the Food and Drug Administration (FDA) and requests urgent approval of it. Although, scientists warned that the new drug may have serious harmful side effects, such as causing cancer and birth defects. If approved, Molnupiravir will be the first drug to treat COVID-19.
The New York Times stated that the drug will completely change the treatment of COVID-19 because it can treat more high-risk patients suffering from COVID-19 at a relatively low price, but Merck is charging up to 40 times what it costs.
Despite the expensive drug being unapproved yet, the contacts of Merck are on a long list, including governments all over the world. Currently, Merck has reached agreements with the United States, South Korea, Singapore, Malaysia, Australia, and governments of many other countries. According to the New York Times, approval may come within a few weeks. It seems that cheap, safe, and effective drugs such as ivermectin and hydroxychloroquine are unlikely to be approved.
(Disclaimer: the above is the author’s opinion and is not the opinion of GNews.)
Proofread/posted by: Lightyear
For More information, follow us on
New York MOS Himalaya ｜GTV
New York MOS Himalaya ｜MOS TALK
New York MOS Himalaya | Gettr
New York MOS Himalaya ｜YouTube